Weight loss induced by GLP-1 receptor agonists like semaglutide often includes a significant loss of lean body mass. Some trials report that up to 40% of total weight lost can be fat-free mass, raising concerns about metabolic rate and physical function (Wilding 2021). This has prompted investigation into peptides that might selectively preserve muscle during caloric deficit.
AOD-9604, a fragment of human growth hormone (hGH 177-191), has drawn attention for its lipolytic properties without the diabetogenic effects of full-length hGH. Preclinical work showed that AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue, with no effect on insulin sensitivity (Ng 2000). In a 12-week human trial of 300 obese subjects, daily oral AOD-9604 at 1 mg produced a mean weight loss of 2.6 kg, compared to 1.2 kg for placebo, without altering IGF-1 levels (Stier 2013).
MOTS-c, a mitochondrial-derived peptide, appears to enhance metabolic flexibility. It promotes glucose utilization and fatty acid oxidation in skeletal muscle, potentially countering the muscle insulin resistance that can accompany rapid weight loss (Lee 2015). In mice, MOTS-c administration prevented high-fat-diet-induced obesity and improved muscle glucose uptake, suggesting a muscle-sparing mechanism during energy restriction (Kim 2018).
The synergy between AOD-9604 and MOTS-c lies in their complementary actions. AOD-9604 targets adipose tissue directly, while MOTS-c improves muscle metabolic health. Together, they might shift the composition of weight loss toward fat, protecting lean mass. However, no clinical trial has tested this combination in humans. Evidence for synergy is limited to mechanistic plausibility and separate animal data.
A 2023 review of mitochondrial peptides noted that MOTS-c levels decline with age and obesity, and that exogenous replacement could enhance exercise capacity and fat oxidation (Reynolds 2023).
Concerns about muscle loss during GLP-1 therapy are not unfounded. In the STEP 1 trial, semaglutide 2.4 mg weekly led to a 15.2 kg weight loss at 68 weeks, but 5.9 kg of that was lean mass (Wilding 2021). This proportion is similar to that seen with other weight loss interventions, but the absolute amount of lean mass lost is higher due to greater total weight loss. Some researchers argue that the functional significance of this lean mass loss is unclear, as strength and physical function often improve with weight loss (Sargeant 2022).
Counter-evidence exists. A meta-analysis of 18 randomized controlled trials found that GLP-1 agonists did not disproportionately reduce lean mass compared to other weight loss methods, when adjusted for total weight loss (Jastreboff 2022). The proportion of lean mass lost was approximately 25-30% of total weight loss, consistent with diet and lifestyle interventions. This suggests that the concern may be overstated, though individual variability is high.
Other peptides have been explored for muscle preservation. Tesamorelin, a growth hormone-releasing hormone analog, reduced visceral fat and improved lean mass in HIV patients with lipodystrophy, but its use in obesity is off-label (Falutz 2007). CJC-1295, a long-acting GHRH analog, has shown similar effects in small studies, but safety data are sparse. Retatrutide, a triple agonist (GLP-1, GIP, glucagon), is in phase 2 trials and appears to promote greater fat loss with less lean mass loss than semaglutide, though data are preliminary (Jastreboff 2023).
The combination of AOD-9604 and MOTS-c remains speculative. AOD-9604 has a favorable safety profile in short-term studies, with no serious adverse events reported at doses up to 25 mg/kg in animals (Ng 2000). MOTS-c has not been tested in long-term human trials. Its effects on muscle mass are inferred from metabolic improvements, not direct measurements of hypertrophy or atrophy.
In a mouse model of diet-induced obesity, MOTS-c treatment for 8 weeks reduced fat mass by 12% while preserving lean mass, compared to a 5% lean mass loss in controls (Kim 2018).
For those using GLP-1 agonists, the addition of resistance exercise and adequate protein intake remains the most evidence-based strategy to preserve muscle. Pharmacological adjuncts like AOD-9604 and MOTS-c may offer theoretical benefits, but human data are lacking. The risk of self-administration of unapproved compounds includes unknown long-term effects and potential interactions with prescribed medications.
Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.